<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00050778</url>
  </required_header>
  <id_info>
    <org_study_id>CAMMS223</org_study_id>
    <nct_id>NCT00050778</nct_id>
  </id_info>
  <brief_title>A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis</brief_title>
  <official_title>A Phase II, Randomized, Open-Label, Three-Arm Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Subcutaneous Interferon Beta-1a (Rebif®) in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a Phase II, randomized, open-label, rater-blinded, three-arm study comparing two
      different doses of alemtuzumab (Lemtrada™) and one dose of subcutaneous (SC) interferon
      beta-1a (Rebif®) in participants with early, active relapsing-remitting multiple sclerosis
      (MS) who had not been previously treated with MS therapies other than steroids. The study was
      conducted for an initial period of 3 years and a follow-up to 5 years or more.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aims of MS therapy are to prevent the progression of disease and accumulation of
      long-term disability. The hypothesis underlying this study was that aggressive treatment of
      inflammation in the brain early in the course of MS would protect the participant from
      disease progression and accumulating disability.

      This protocol compared two different doses of alemtuzumab and high-dose, high frequency of SC
      interferon beta-1a to evaluate the safety profiles of the respective treatments and to
      evaluate efficacy in terms of:

        -  Slowing the sustained accumulation of disability in participant with MS;

        -  Reducing the frequency of relapses experienced by participant with MS; and

        -  Reducing the harmful effects of MS on the brain, as assessed by magnetic resonance
           imaging (MRI)

      Participants who received alemtuzumab during the initial 36-month treatment period may have
      been eligible for re-treatment with alemtuzumab in the extension study CAMMS03409
      (NCT00930553) to evaluate:

        -  How long the effects of prior alemtuzumab treatment lasted;

        -  If additional treatments with alemtuzumab continued to reduce the effects of MS; and

        -  What kind of side effects participants experienced upon retreatment with alemtuzumab
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2002</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Probability of Participants With Sustained Accumulation of Disability (SAD)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>EDSS is an ordinal scale in half-point increments that quantifies disability in participants with MS. It assesses 7 functional systems (visual, brainstem, pyramidal, cerebellar, sensory, bowel/bladder and cerebral) as well as ambulation. EDSS total score: 0 (normal neurological examination) to 10 (death due to MS). As measured by EDSS score, SAD was defined as increase of at least 1.5 points for participants with Baseline score of 0 and increase of at least 1.0 point for participants with Baseline score of 1.0 or more; and the increase persisted for at least next the 2 scheduled assessments, that is, 6 consecutive months. The onset date of SAD was date of first EDSS assessment that began 6 month consecutive period of SAD. Participants who did not reach SAD endpoint were censored at their last visit. Probability of participants with SAD, estimated by Kaplan-Meier (KM) method, was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Annualized Relapse Rate</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Relapse was defined as new neurological symptoms or worsening of previous neurological symptoms with an objective change on neurological examination, attributable to multiple sclerosis that lasted for at least 48 hours, that were present at normal body temperature, and that were preceded by at least 30 days of clinical stability. Annualized relapse rate was estimated using a Poisson regression model with observed number of relapses as a dependent variable, the log total amount of follow-up from date of randomization for each participant as an offset variable and treatment group indicator as a covariate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Probability of Participants Who Were Relapse Free at 3 Years After Initial Treatment</measure>
    <time_frame>Year 3</time_frame>
    <description>Participants were considered relapse free at Year 3 if they did not experience a relapse between randomization and study completion at 36 months. Participants who discontinued early were considered relapse free if they did not experience a relapse prior to discontinuation. Probability of participants who were relapse free at Year 3, estimated using the KM method, was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in T1 Cerebral Volume at Year 3</measure>
    <time_frame>Baseline, Year 3</time_frame>
    <description>Magnetic resonance imaging (MRI) T1 was used to determine rate of cerebral atrophy (decrease in cerebral/brain volume). Partial brain volumes were measured using the technique of Losseff et al. (1996). Percent change in cerebral volume at Year 3 was calculated from MRI-T1-weighted scans as: 100*([brain volume at Year 3] minus [brain volume at Baseline]) divided by [brain volume at Baseline]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in MRI T2 Lesion Volume at Year 3</measure>
    <time_frame>Baseline, Year 3</time_frame>
    <description>Percent change in lesion volume at Year 3 was calculated from MRI-T2-weighted scans as: 100*([lesion volume at Year 3] minus [lesion volume at Baseline]) divided by [lesion volume at Baseline]).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">334</enrollment>
  <condition>Multiple Sclerosis, Relapsing-Remitting</condition>
  <arm_group>
    <arm_group_label>Interferon Beta-1a</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Alemtuzumab 12 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Alemtuzumab 24 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Interferon beta-1a</intervention_name>
    <description>Interferon beta-1a 44 microgram (mcg) subcutaneously 3-times weekly for 36 months.</description>
    <arm_group_label>Interferon Beta-1a</arm_group_label>
    <other_name>Rebif®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Alemtuzumab 12 mg</intervention_name>
    <description>Alemtuzumab 12 milligram per day (mg/day) was given by intravenous infusion on 5 consecutive days during the first month and on 3 consecutive days at months 12 and 24 (the latter at the treating physicians' discretion if the cluster of differentiation 4+ [CD4+] T-cell count was &gt;=100*10^6 cells per liter).</description>
    <arm_group_label>Alemtuzumab 12 mg</arm_group_label>
    <other_name>Lemtrada</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Alemtuzumab 24 mg</intervention_name>
    <description>Alemtuzumab 24 mg/day was given by intravenous infusion on 5 consecutive days during the first month and on 3 consecutive days at months 12 and 24 (the latter at the treating physicians' discretion if the CD4+ T-cell count was &gt;=100*10^6 cells per liter).</description>
    <arm_group_label>Alemtuzumab 24 mg</arm_group_label>
    <other_name>Lemtrada</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent form (ICF)

          -  Male or non-pregnant, non-lactating female participants, 18 to 50 years of age
             (inclusive) as of signing the ICF

          -  Diagnosis of MS per McDonald's update of the Poser criteria, including cranial MRI
             consistent with those criteria (McDonald, 2001, Ann Neurol)

          -  Onset of first MS symptoms within 3 years prior to Screening as of signing the ICF

          -  Expanded Disability Status Scale (EDSS) score 0.0 to 3.0 (inclusive) at the screening
             and Baseline visits

          -  At least 2 completed clinical episodes of MS in the 2 years prior to study entry (that
             is, the initial event if within 2 years of study entry plus at least 1 relapse, or at
             least 2 relapses if the initial event was between 2 and 3 years prior to study entry)

          -  In addition to the clinical criteria, at least 1 enhancing lesion on any 1 of up to 4
             screening gadolinium-enhanced MRI brain scans during a maximum 3-month run-in period
             (inclusive of the Month 0 Baseline scan)

        Exclusion Criteria:

          -  Previous immunotherapy for MS other than steroids, including treatment with
             interferons, intravenous immunoglobulin (IVIG), glatiramer acetate, and mitoxantrone

          -  Personal history of thyroid autoimmune disease

          -  Personal history of clinically significant autoimmune disease (for example,
             inflammatory bowel disease, diabetes, lupus, severe asthma)

          -  History of thyroid carcinoma (previous thyroid adenoma was acceptable and was not
             considered an exclusion criterion)

          -  History of malignancy (except for basal cell skin carcinoma if disease-free for at
             least 5 years)

          -  Any disability acquired from trauma or another illness that, in the opinion of the
             Investigator, interfered with evaluation of disability due to MS

          -  Previous treatment with alemtuzumab

          -  History of anaphylaxis following exposure to humanized monoclonal antibodies

          -  Inability to undergo MRI with gadolinium administration

          -  Female participants of childbearing potential with a positive serum pregnancy test at
             screening or Baseline

          -  Male and female participants who did not agree to use effective contraceptive
             method(s) during the study

          -  Impaired renal function (that is, serum creatinine greater than or equal to 2 times
             the upper limit of normal [ULN])

          -  Untreated, major depressive disorder

          -  Epileptic seizures that were not adequately controlled by treatment

          -  Suicidal ideation

          -  Major systemic disease or other illness that, in the opinion of the Investigator, have
             compromised participant safety or interfered with the interpretation of study results

          -  Abnormal CD4 count or significantly abnormal thyroid function; presence of
             anti-thyroid stimulating hormone (TSH) receptor antibodies; known seropositivity for
             human immunodeficiency (HIV)

          -  Intolerance of pulsed corticosteroids, especially a history of steroid psychosis

          -  Presence of a monoclonal paraprotein

          -  Participants who had any form of MS other than relapsing-remitting

          -  Participants currently participating in a clinical study of an experimental or
             unapproved/unlicensed therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Genzyme, a Sanofi Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic Scottsdale Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials, Inc</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Bay Physicians Medical Group</name>
      <address>
        <city>Berkeley</city>
        <state>California</state>
        <zip>94705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nerve Pro Research</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuro-Therapeutics, Inc.</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurological Research Institute of the East Bay</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>938-1343</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologic Research Institute/Mile High Research Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurological Service of Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurological Associates/ Research Dept.</name>
      <address>
        <city>Pompano Beach</city>
        <state>Florida</state>
        <zip>33060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Clinical Research, Inc.</name>
      <address>
        <city>Sunrise</city>
        <state>Florida</state>
        <zip>3335-6637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Axiom Clinical Research of Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Research and Health Education</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultants in Neurology, Ltd</name>
      <address>
        <city>Northbrook</city>
        <state>Illinois</state>
        <zip>60062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fort Wayne Neurological Center</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associate in Neurology</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland -Maryland Center for MS</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University Department of Neurology</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan Institute for Neurological Disorders</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan Medical P.C. Neurology</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49525</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester Department of Neurology</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nevada Neurological Consultants, Ltd.</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital an Medical Center</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ALL-Trials Clinical Research, LLC</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurological Associates of Tulsa, Inc</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74137</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurosciencies and Pain Research</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103-6296</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology, PC</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37934</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dallas Neurological Associate</name>
      <address>
        <city>Richardson</city>
        <state>Texas</state>
        <zip>75080</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Texas Neurology Consultants PA</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78681</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Integra Clinical Research, LLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Center of San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, University Hospital &quot;Osijek&quot;</name>
      <address>
        <city>Osijek</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Clinical Hospital Centre &quot;Rijeka&quot;</name>
      <address>
        <city>Rijeka</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Clinical Hospital Centre &quot;Zagreb&quot;</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, General Hospital &quot;Sveti Duh&quot;</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, University Hopsital &quot;Sestre Milosrdnice&quot;</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Neurologii Klinicznej</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Zakład Opieki Zdrowotnej</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Neurologii</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oddzial Kliniczny Neurologii</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instytut Psychiatrii i Neurologii</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Katedra i Klinika Neurologii</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Russian State Medical University</name>
      <address>
        <city>Moscow</city>
        <zip>117437</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Scientific Center RAMS</name>
      <address>
        <city>Moscow</city>
        <zip>125367</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow City Hospital #11</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow City Hospital #61</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Human brain RAS</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197376</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Petersburg State Pavlov Medical University</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <state>England</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Croatia</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003718/WC500150521.pdf</url>
    <description>http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003718/WC500150521.pdf</description>
  </link>
  <reference>
    <citation>Coles AJ, Cox A, Le Page E, Jones J, Trip SA, Deans J, Seaman S, Miller DH, Hale G, Waldmann H, Compston DA. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol. 2006 Jan;253(1):98-108. Epub 2005 Jul 27.</citation>
    <PMID>16044212</PMID>
  </reference>
  <results_reference>
    <citation>CAMMS223 Trial Investigators, Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, Margolin DH, Norris K, Tandon PK. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008 Oct 23;359(17):1786-801. doi: 10.1056/NEJMoa0802670.</citation>
    <PMID>18946064</PMID>
  </results_reference>
  <results_reference>
    <citation>Daniels GH, Vladic A, Brinar V, Zavalishin I, Valente W, Oyuela P, Palmer J, Margolin DH, Hollenstein J. Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis. J Clin Endocrinol Metab. 2014 Jan;99(1):80-9. doi: 10.1210/jc.2013-2201. Epub 2013 Dec 20.</citation>
    <PMID>24170099</PMID>
  </results_reference>
  <results_reference>
    <citation>Graves J, Galetta SL, Palmer J, Margolin DH, Rizzo M, Bilbruck J, Balcer LJ. Alemtuzumab improves contrast sensitivity in patients with relapsing-remitting multiple sclerosis. Mult Scler. 2013 Sep;19(10):1302-9. doi: 10.1177/1352458513475722. Epub 2013 Mar 4.</citation>
    <PMID>23459567</PMID>
  </results_reference>
  <results_reference>
    <citation>Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, Skoromets A, Stolyarov I, Bass A, Sullivan H, Margolin DH, Lake SL, Moran S, Palmer J, Smith MS, Compston DA. Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology. 2012 Apr 3;78(14):1069-78. doi: 10.1212/WNL.0b013e31824e8ee7. Epub 2012 Mar 21.</citation>
    <PMID>22442431</PMID>
  </results_reference>
  <results_reference>
    <citation>Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, Bass AD, Wynn DR, Margolin DH, Lake SL, Moran S, Palmer J, Smith MS, Compston DA. Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes. Lancet Neurol. 2011 Apr;10(4):338-48. doi: 10.1016/S1474-4422(11)70020-5.</citation>
    <PMID>21397567</PMID>
  </results_reference>
  <results_reference>
    <citation>Jones JL, Anderson JM, Phuah CL, Fox EJ, Selmaj K, Margolin D, Lake SL, Palmer J, Thompson SJ, Wilkins A, Webber DJ, Compston DA, Coles AJ. Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity. Brain. 2010 Aug;133(Pt 8):2232-47. doi: 10.1093/brain/awq176. Epub 2010 Jul 21.</citation>
    <PMID>20659956</PMID>
  </results_reference>
  <results_reference>
    <citation>Cuker A, Coles AJ, Sullivan H, Fox E, Goldberg M, Oyuela P, Purvis A, Beardsley DS, Margolin DH. A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis. Blood. 2011 Dec 8;118(24):6299-305. doi: 10.1182/blood-2011-08-371138. Epub 2011 Sep 29.</citation>
    <PMID>21960587</PMID>
  </results_reference>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2002</study_first_submitted>
  <study_first_submitted_qc>December 20, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2002</study_first_posted>
  <results_first_submitted>November 3, 2008</results_first_submitted>
  <results_first_submitted_qc>July 13, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 25, 2009</results_first_posted>
  <last_update_submitted>January 6, 2015</last_update_submitted>
  <last_update_submitted_qc>January 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Active Relapsing-Remitting Multiple Sclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alemtuzumab</mesh_term>
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-beta</mesh_term>
    <mesh_term>Interferon beta-1a</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 49 investigational sites in the United States, United Kingdom, and Eastern Europe between December 04, 2002 and January 12, 2010.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Interferon Beta-1a</title>
          <description>Interferon beta-1a (Rebif®) 44 micrograms (mcg) subcutaneously 3-times weekly for 36 months.</description>
        </group>
        <group group_id="P2">
          <title>Alemtuzumab 12 mg</title>
          <description>Alemtuzumab (Lemtrada™) 12 milligram per day (mg/day) was given by intravenous infusion on 5 consecutive days during the first month and on 3 consecutive days at months 12 and 24 (the latter at the treating physicians’ discretion if the cluster of differentiation 4+ [CD4+] T-cell count was &gt;=100*10^6 cells per liter).</description>
        </group>
        <group group_id="P3">
          <title>Alemtuzumab 24 mg</title>
          <description>Alemtuzumab 24 mg/day was given by intravenous infusion on 5 consecutive days during the first month and on 3 consecutive days at months 12 and 24 (the latter at the treating physicians’ discretion if the CD4+ T-cell count was &gt;=100*10^6 cells per liter).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="111">Randomized.</participants>
                <participants group_id="P2" count="113"/>
                <participants group_id="P3" count="110"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="107"/>
                <participants group_id="P2" count="108"/>
                <participants group_id="P3" count="108"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="92"/>
                <participants group_id="P3" count="92"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized but not treated</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Familial and personal reasons</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>FAS population included all randomized participants who had correct diagnosis of MS at entry. One participant was included in safety but excluded from efficacy analysis as initial multiple sclerosis diagnosis was incorrect.</population>
      <group_list>
        <group group_id="B1">
          <title>Interferon Beta-1a</title>
          <description>Interferon beta-1a 44 mcg subcutaneously 3-times weekly for 36 months.</description>
        </group>
        <group group_id="B2">
          <title>Alemtuzumab 12 mg</title>
          <description>Alemtuzumab 12 mg/day was given by intravenous infusion on 5 consecutive days during the first month and on 3 consecutive days at months 12 and 24 (the latter at the treating physicians' discretion if the CD4+ T-cell count was &gt;=100*10^6 cells per liter).</description>
        </group>
        <group group_id="B3">
          <title>Alemtuzumab 24 mg</title>
          <description>Alemtuzumab 24 mg/day was given by intravenous infusion on 5 consecutive days during the first month and on 3 consecutive days at months 12 and 24 (the latter at the treating physicians' discretion if the CD4+ T-cell count was &gt;=100*10^6 cells per liter).</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="111"/>
            <count group_id="B2" value="112"/>
            <count group_id="B3" value="110"/>
            <count group_id="B4" value="333"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.8" spread="8.82"/>
                    <measurement group_id="B2" value="31.9" spread="8.01"/>
                    <measurement group_id="B3" value="32.2" spread="8.76"/>
                    <measurement group_id="B4" value="32.3" spread="8.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="71"/>
                    <measurement group_id="B4" value="214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time Since First Relapse</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.4" lower_limit="0.2" upper_limit="6.3"/>
                    <measurement group_id="B2" value="1.3" lower_limit="0.1" upper_limit="3.5"/>
                    <measurement group_id="B3" value="1.2" lower_limit="0.3" upper_limit="3.2"/>
                    <measurement group_id="B4" value="1.3" lower_limit="0.1" upper_limit="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Relapse Episodes in the Preceding 2 Years</title>
          <description>Number of participants with 0, 1, 2 or greater than or equal to 3 relapses are reported.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0 Relapse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Relapse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Relapses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="56"/>
                    <measurement group_id="B4" value="187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greater than or equal to 3 Relapses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Number of Relapses</title>
          <units>relapses</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="293"/>
                    <measurement group_id="B2" value="301"/>
                    <measurement group_id="B3" value="290"/>
                    <measurement group_id="B4" value="884"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Expanded Disability Status Scale (EDSS) Score</title>
          <description>EDSS is an ordinal scale in half-point increments that quantifies disability in participants with MS. It assesses the 7 functional systems (visual, brainstem, pyramidal, cerebellar, sensory, bowel/bladder and cerebral) as well as ambulation. EDSS total score ranges from 0 (normal neurological examination) to 10 (death due to MS). Number of participants evaluable for this Baseline characteristic were 110, 112 and 110 in Interferon Beta-1a, Alemtuzumab 12 mg and Alemtuzumab 24 mg arm, respectively.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.9" spread="0.81"/>
                    <measurement group_id="B2" value="2.0" spread="0.73"/>
                    <measurement group_id="B3" value="2.0" spread="0.73"/>
                    <measurement group_id="B4" value="1.9" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time Constant 1 (T1) Cerebral Volume</title>
          <description>Number of participants evaluable for this Baseline characteristic were 103, 107 and 107 in Interferon Beta-1a, Alemtuzumab 12 mg and Alemtuzumab 24 mg arm, respectively. Partial brain volumes were measured using the technique of Losseff et al. (1996).</description>
          <units>cubic centimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="317.5" spread="24.70"/>
                    <measurement group_id="B2" value="320.8" spread="27.15"/>
                    <measurement group_id="B3" value="320.5" spread="24.99"/>
                    <measurement group_id="B4" value="319.6" spread="25.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time Constant 2 (T2) Lesion Volume</title>
          <description>Number of participants evaluable for this Baseline characteristic were 102, 106 and 107 in Interferon Beta-1a, Alemtuzumab 12 mg and Alemtuzumab 24 mg arm, respectively.</description>
          <units>cubic centimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.8" spread="15.23"/>
                    <measurement group_id="B2" value="17.2" spread="23.84"/>
                    <measurement group_id="B3" value="17.8" spread="17.45"/>
                    <measurement group_id="B4" value="17.0" spread="19.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Probability of Participants With Sustained Accumulation of Disability (SAD)</title>
        <description>EDSS is an ordinal scale in half-point increments that quantifies disability in participants with MS. It assesses 7 functional systems (visual, brainstem, pyramidal, cerebellar, sensory, bowel/bladder and cerebral) as well as ambulation. EDSS total score: 0 (normal neurological examination) to 10 (death due to MS). As measured by EDSS score, SAD was defined as increase of at least 1.5 points for participants with Baseline score of 0 and increase of at least 1.0 point for participants with Baseline score of 1.0 or more; and the increase persisted for at least next the 2 scheduled assessments, that is, 6 consecutive months. The onset date of SAD was date of first EDSS assessment that began 6 month consecutive period of SAD. Participants who did not reach SAD endpoint were censored at their last visit. Probability of participants with SAD, estimated by Kaplan-Meier (KM) method, was reported.</description>
        <time_frame>Up to 3 years</time_frame>
        <population>Full Analysis Set (FAS) population included all randomized participants who had correct diagnosis of MS at entry.</population>
        <group_list>
          <group group_id="O1">
            <title>Interferon Beta-1a</title>
            <description>Interferon Beta-1a 44 mcg subcutaneously 3-times weekly for 36 months.</description>
          </group>
          <group group_id="O2">
            <title>Alemtuzumab 12 mg</title>
            <description>Alemtuzumab 12 mg/day was given by intravenous infusion on 5 consecutive days during the first month and on 3 consecutive days at months 12 and 24 (the latter at the treating physicians’ discretion if the CD4+ T-cell count was &gt;=100*10^6 cells per liter).</description>
          </group>
          <group group_id="O3">
            <title>Alemtuzumab 24 mg</title>
            <description>Alemtuzumab 24 mg/day was given by intravenous infusion on 5 consecutive days during the first month and on 3 consecutive days at months 12 and 24 (the latter at the treating physicians’ discretion if the CD4+ T-cell count was &gt;=100*10^6 cells per liter).</description>
          </group>
          <group group_id="O4">
            <title>Alemtuzumab (Pooled)</title>
            <description>Included all participants who received alemtuzumab 12 mg/day or 24 mg/day by intravenous infusion on 5 consecutive days during first month and on 3 consecutive days at months 12 and 24 (the latter at the treating physicians’ discretion if the CD4+ T-cell count was &gt;=100*10^6 cells per liter).</description>
          </group>
        </group_list>
        <measure>
          <title>Probability of Participants With Sustained Accumulation of Disability (SAD)</title>
          <description>EDSS is an ordinal scale in half-point increments that quantifies disability in participants with MS. It assesses 7 functional systems (visual, brainstem, pyramidal, cerebellar, sensory, bowel/bladder and cerebral) as well as ambulation. EDSS total score: 0 (normal neurological examination) to 10 (death due to MS). As measured by EDSS score, SAD was defined as increase of at least 1.5 points for participants with Baseline score of 0 and increase of at least 1.0 point for participants with Baseline score of 1.0 or more; and the increase persisted for at least next the 2 scheduled assessments, that is, 6 consecutive months. The onset date of SAD was date of first EDSS assessment that began 6 month consecutive period of SAD. Participants who did not reach SAD endpoint were censored at their last visit. Probability of participants with SAD, estimated by Kaplan-Meier (KM) method, was reported.</description>
          <population>Full Analysis Set (FAS) population included all randomized participants who had correct diagnosis of MS at entry.</population>
          <units>probability of participants with SAD</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="110"/>
                <count group_id="O4" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27" lower_limit="0.193" upper_limit="0.380"/>
                    <measurement group_id="O2" value="0.08" lower_limit="0.043" upper_limit="0.165"/>
                    <measurement group_id="O3" value="0.09" lower_limit="0.052" upper_limit="0.169"/>
                    <measurement group_id="O4" value="0.09" lower_limit="0.057" upper_limit="0.139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cox proportional hazards (PH) regression model using treatment group, Baseline EDSS group (grouped by less than or equal to 1.5 and greater than 1.5), and country (investigative center grouped by country) as covariates was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <p_value_desc>An alpha-sharing approach was used to adjust for multiple treatment group comparisons, endpoints, and two pre-planned interim analyses, including a Lan-Demets error-spending function. Pre-specified threshold for statistical significance was 0.0165.</p_value_desc>
            <method>Cox Proportional Hazards Regression</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.110</ci_lower_limit>
            <ci_upper_limit>0.545</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Cox PH regression model using treatment group, Baseline EDSS group (grouped by less than or equal to 1.5 and greater than 1.5), and country (investigative center grouped by country) as covariates was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0021</p_value>
            <p_value_desc>An alpha-sharing approach was used to adjust for multiple treatment group comparisons, endpoints, and two pre-planned interim analyses, including a Lan-Demets error-spending function. Pre-specified threshold for statistical significance was 0.0165.</p_value_desc>
            <method>Cox Proportional Hazards Regression</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.151</ci_lower_limit>
            <ci_upper_limit>0.658</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Cox PH regression model using treatment group, Baseline EDSS group (grouped by less than or equal to 1.5 and greater than 1.5), and country (investigative center grouped by country) as covariates was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cox Proportional Hazards Regression</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.152</ci_lower_limit>
            <ci_upper_limit>0.515</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Annualized Relapse Rate</title>
        <description>Relapse was defined as new neurological symptoms or worsening of previous neurological symptoms with an objective change on neurological examination, attributable to multiple sclerosis that lasted for at least 48 hours, that were present at normal body temperature, and that were preceded by at least 30 days of clinical stability. Annualized relapse rate was estimated using a Poisson regression model with observed number of relapses as a dependent variable, the log total amount of follow-up from date of randomization for each participant as an offset variable and treatment group indicator as a covariate.</description>
        <time_frame>Up to 3 years</time_frame>
        <population>FAS population included all randomized participants who had correct diagnosis of MS at entry.</population>
        <group_list>
          <group group_id="O1">
            <title>Interferon Beta-1a</title>
            <description>Interferon Beta-1a 44 mcg subcutaneously 3-times weekly for 36 months.</description>
          </group>
          <group group_id="O2">
            <title>Alemtuzumab 12 mg</title>
            <description>Alemtuzumab 12 mg/day was given by intravenous infusion on 5 consecutive days during the first month and on 3 consecutive days at months 12 and 24 (the latter at the treating physicians’ discretion if the CD4+ T-cell count was &gt;=100*10^6 cells per liter).</description>
          </group>
          <group group_id="O3">
            <title>Alemtuzumab 24 mg</title>
            <description>Alemtuzumab 24 mg/day was given by intravenous infusion on 5 consecutive days during the first month and on 3 consecutive days at months 12 and 24 (the latter at the treating physicians’ discretion if the CD4+ T-cell count was &gt;=100*10^6 cells per liter).</description>
          </group>
          <group group_id="O4">
            <title>Alemtuzumab (Pooled)</title>
            <description>Included all participants who received alemtuzumab 12 mg/day or 24 mg/day by intravenous infusion on 5 consecutive days during first month and on 3 consecutive days at months 12 and 24 (the latter at the treating physicians’ discretion if the CD4+ T-cell count was &gt;=100*10^6 cells per liter).</description>
          </group>
        </group_list>
        <measure>
          <title>Annualized Relapse Rate</title>
          <description>Relapse was defined as new neurological symptoms or worsening of previous neurological symptoms with an objective change on neurological examination, attributable to multiple sclerosis that lasted for at least 48 hours, that were present at normal body temperature, and that were preceded by at least 30 days of clinical stability. Annualized relapse rate was estimated using a Poisson regression model with observed number of relapses as a dependent variable, the log total amount of follow-up from date of randomization for each participant as an offset variable and treatment group indicator as a covariate.</description>
          <population>FAS population included all randomized participants who had correct diagnosis of MS at entry.</population>
          <units>relapses per participant per year</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="110"/>
                <count group_id="O4" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.37" lower_limit="0.297" upper_limit="0.449"/>
                    <measurement group_id="O2" value="0.12" lower_limit="0.091" upper_limit="0.171"/>
                    <measurement group_id="O3" value="0.09" lower_limit="0.064" upper_limit="0.133"/>
                    <measurement group_id="O4" value="0.11" lower_limit="0.085" upper_limit="0.137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment effects were estimated using an Anderson-Gill multiplicative intensity model with robust variance estimation. Covariates included treatment group, Baseline EDSS group (grouped by less than or equal to 1.5 and greater than 1.5), and country (investigative center grouped by country).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>An alpha-sharing approach was used to adjust for multiple treatment group comparisons, endpoints, and two pre-planned interim analyses, including a Lan-Demets error-spending function. Pre-specified threshold for statistical significance was 0.0040.</p_value_desc>
            <method>Andersen-Gill Model</method>
            <param_type>Rate ratio</param_type>
            <param_value>0.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.196</ci_lower_limit>
            <ci_upper_limit>0.552</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment effects were estimated using an Anderson-Gill multiplicative intensity model with robust variance estimation. Covariates included treatment group, Baseline EDSS group (grouped by less than or equal to 1.5 and greater than 1.5), and country (investigative center grouped by country).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>An alpha-sharing approach was used to adjust for multiple treatment group comparisons, endpoints, and two pre-planned interim analyses, including a Lan-Demets error-spending function. Pre-specified threshold for statistical significance was 0.0040.</p_value_desc>
            <method>Andersen-Gill Model</method>
            <param_type>Rate ratio</param_type>
            <param_value>0.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.126</ci_lower_limit>
            <ci_upper_limit>0.431</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Treatment effects were estimated using an Anderson-Gill multiplicative intensity model with robust variance estimation. Covariates included treatment group, Baseline EDSS group (grouped by less than or equal to 1.5 and greater than 1.5), and country (investigative center grouped by country).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Andersen-Gill Model</method>
            <param_type>Rate ratio</param_type>
            <param_value>0.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.176</ci_lower_limit>
            <ci_upper_limit>0.441</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Probability of Participants Who Were Relapse Free at 3 Years After Initial Treatment</title>
        <description>Participants were considered relapse free at Year 3 if they did not experience a relapse between randomization and study completion at 36 months. Participants who discontinued early were considered relapse free if they did not experience a relapse prior to discontinuation. Probability of participants who were relapse free at Year 3, estimated using the KM method, was reported.</description>
        <time_frame>Year 3</time_frame>
        <population>FAS population included all randomized participants who had correct diagnosis of MS at entry.</population>
        <group_list>
          <group group_id="O1">
            <title>Interferon Beta-1a</title>
            <description>Interferon Beta-1a 44 mcg subcutaneously 3-times weekly for 36 months.</description>
          </group>
          <group group_id="O2">
            <title>Alemtuzumab 12 mg</title>
            <description>Alemtuzumab 12 mg/day was given by intravenous infusion on 5 consecutive days during the first month and on 3 consecutive days at months 12 and 24 (the latter at the treating physicians’ discretion if the CD4+ T-cell count was &gt;=100*10^6 cells per liter).</description>
          </group>
          <group group_id="O3">
            <title>Alemtuzumab 24 mg</title>
            <description>Alemtuzumab 24 mg/day was given by intravenous infusion on 5 consecutive days during the first month and on 3 consecutive days at months 12 and 24 (the latter at the treating physicians’ discretion if the CD4+ T-cell count was &gt;=100*10^6 cells per liter).</description>
          </group>
          <group group_id="O4">
            <title>Alemtuzumab (Pooled)</title>
            <description>Included all participants who received alemtuzumab 12 mg/day or 24 mg/day by intravenous infusion on 5 consecutive days during first month and on 3 consecutive days at months 12 and 24 (the latter at the treating physicians’ discretion if the CD4+ T-cell count was &gt;=100*10^6 cells per liter).</description>
          </group>
        </group_list>
        <measure>
          <title>Probability of Participants Who Were Relapse Free at 3 Years After Initial Treatment</title>
          <description>Participants were considered relapse free at Year 3 if they did not experience a relapse between randomization and study completion at 36 months. Participants who discontinued early were considered relapse free if they did not experience a relapse prior to discontinuation. Probability of participants who were relapse free at Year 3, estimated using the KM method, was reported.</description>
          <population>FAS population included all randomized participants who had correct diagnosis of MS at entry.</population>
          <units>probability of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="110"/>
                <count group_id="O4" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" lower_limit="0.395" upper_limit="0.602"/>
                    <measurement group_id="O2" value="0.76" lower_limit="0.667" upper_limit="0.832"/>
                    <measurement group_id="O3" value="0.84" lower_limit="0.748" upper_limit="0.894"/>
                    <measurement group_id="O4" value="0.80" lower_limit="0.737" upper_limit="0.847"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cox PH regression model with treatment group indicator, Baseline EDSS and country as covariates was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Cox Proportional Hazards Regression</method>
            <param_type>Treatment effect</param_type>
            <param_value>62.64</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Cox PH regression model with treatment group indicator, Baseline EDSS and country as covariates was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cox Proportional Hazards Regression</method>
            <param_type>Treatment effect</param_type>
            <param_value>76.71</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Cox PH regression model with treatment group indicator, Baseline EDSS and country as covariates was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cox Proportional Hazards Regression</method>
            <param_type>Treatment effect</param_type>
            <param_value>70.13</param_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in T1 Cerebral Volume at Year 3</title>
        <description>Magnetic resonance imaging (MRI) T1 was used to determine rate of cerebral atrophy (decrease in cerebral/brain volume). Partial brain volumes were measured using the technique of Losseff et al. (1996). Percent change in cerebral volume at Year 3 was calculated from MRI-T1-weighted scans as: 100*([brain volume at Year 3] minus [brain volume at Baseline]) divided by [brain volume at Baseline]).</description>
        <time_frame>Baseline, Year 3</time_frame>
        <population>Analysis population included participants in the FAS population (randomized with a correct diagnosis of MS) who had an evaluable scan for MRI-T1 brain volume at Baseline and Year 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Interferon Beta-1a</title>
            <description>Interferon Beta-1a 44 mcg subcutaneously 3-times weekly for 36 months.</description>
          </group>
          <group group_id="O2">
            <title>Alemtuzumab 12 mg</title>
            <description>Alemtuzumab 12 mg/day was given by intravenous infusion on 5 consecutive days during the first month and on 3 consecutive days at months 12 and 24 (the latter at the treating physicians’ discretion if the CD4+ T-cell count was &gt;=100*10^6 cells per liter).</description>
          </group>
          <group group_id="O3">
            <title>Alemtuzumab 24 mg</title>
            <description>Alemtuzumab 24 mg/day was given by intravenous infusion on 5 consecutive days during the first month and on 3 consecutive days at months 12 and 24 (the latter at the treating physicians’ discretion if the CD4+ T-cell count was &gt;=100*10^6 cells per liter).</description>
          </group>
          <group group_id="O4">
            <title>Alemtuzumab (Pooled)</title>
            <description>Included all participants who received alemtuzumab 12 mg/day or 24 mg/day by intravenous infusion on 5 consecutive days during first month and on 3 consecutive days at months 12 and 24 (the latter at the treating physicians’ discretion if the CD4+ T-cell count was &gt;=100*10^6 cells per liter).</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in T1 Cerebral Volume at Year 3</title>
          <description>Magnetic resonance imaging (MRI) T1 was used to determine rate of cerebral atrophy (decrease in cerebral/brain volume). Partial brain volumes were measured using the technique of Losseff et al. (1996). Percent change in cerebral volume at Year 3 was calculated from MRI-T1-weighted scans as: 100*([brain volume at Year 3] minus [brain volume at Baseline]) divided by [brain volume at Baseline]).</description>
          <population>Analysis population included participants in the FAS population (randomized with a correct diagnosis of MS) who had an evaluable scan for MRI-T1 brain volume at Baseline and Year 3.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="90"/>
                <count group_id="O4" value="173"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="4.48"/>
                    <measurement group_id="O2" value="-0.8" spread="3.66"/>
                    <measurement group_id="O3" value="-0.4" spread="4.27"/>
                    <measurement group_id="O4" value="-0.6" spread="3.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ranked analysis of covariance (ANCOVA) model using Baseline MRI-T1 brain volume, EDSS group, country, and treatment as covariates was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0885</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Ranked ANCOVA model using Baseline MRI-T1 brain volume, EDSS group, country, and treatment as covariates was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0195</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Ranked ANCOVA model using Baseline MRI-T1 brain volume, EDSS group, country, and treatment as covariates was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0215</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in MRI T2 Lesion Volume at Year 3</title>
        <description>Percent change in lesion volume at Year 3 was calculated from MRI-T2-weighted scans as: 100*([lesion volume at Year 3] minus [lesion volume at Baseline]) divided by [lesion volume at Baseline]).</description>
        <time_frame>Baseline, Year 3</time_frame>
        <population>Analysis population included participants in the FAS population (randomized with a correct diagnosis of MS) who had an evaluable scan for MRI-T2 lesion volume at Baseline and Year 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Interferon Beta-1a</title>
            <description>Interferon Beta-1a 44 mcg subcutaneously 3-times weekly for 36 months.</description>
          </group>
          <group group_id="O2">
            <title>Alemtuzumab 12 mg</title>
            <description>Alemtuzumab 12 mg/day was given by intravenous infusion on 5 consecutive days during the first month and on 3 consecutive days at months 12 and 24 (the latter at the treating physicians’ discretion if the CD4+ T-cell count was &gt;=100*10^6 cells per liter).</description>
          </group>
          <group group_id="O3">
            <title>Alemtuzumab 24 mg</title>
            <description>Alemtuzumab 24 mg/day was given by intravenous infusion on 5 consecutive days during the first month and on 3 consecutive days at months 12 and 24 (the latter at the treating physicians’ discretion if the CD4+ T-cell count was &gt;=100*10^6 cells per liter).</description>
          </group>
          <group group_id="O4">
            <title>Alemtuzumab (Pooled)</title>
            <description>Included all participants who received alemtuzumab 12 mg/day or 24 mg/day by intravenous infusion on 5 consecutive days during first month and on 3 consecutive days at months 12 and 24 (the latter at the treating physicians’ discretion if the CD4+ T-cell count was &gt;=100*10^6 cells per liter).</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in MRI T2 Lesion Volume at Year 3</title>
          <description>Percent change in lesion volume at Year 3 was calculated from MRI-T2-weighted scans as: 100*([lesion volume at Year 3] minus [lesion volume at Baseline]) divided by [lesion volume at Baseline]).</description>
          <population>Analysis population included participants in the FAS population (randomized with a correct diagnosis of MS) who had an evaluable scan for MRI-T2 lesion volume at Baseline and Year 3.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="88"/>
                <count group_id="O4" value="169"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.4" spread="134.3"/>
                    <measurement group_id="O2" value="-11.4" spread="38.8"/>
                    <measurement group_id="O3" value="-8.9" spread="41.1"/>
                    <measurement group_id="O4" value="-10.1" spread="39.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ranked ANCOVA model using Baseline MRI-T2 lesion volume, EDSS group, country, and treatment as covariates was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3077</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Ranked ANCOVA model using Baseline MRI-T2 lesion volume, EDSS group, country, and treatment as covariates was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3632</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Ranked ANCOVA model using Baseline MRI-T2 lesion volume, EDSS group, country, and treatment as covariates was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2758</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>First dose of study drug up to last follow-up (80.6 months)</time_frame>
      <desc>If a participant experienced both a serious and a non-serious event with the same adverse event term, the individual has been included in the numerator (&quot;number of affected participants&quot;) of both adverse event tables. The analysis was performed on the safety population, defined as all participants who received any amount of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Interferon Beta-1a</title>
          <description>Interferon Beta-1a 44 mcg subcutaneously 3-times weekly for 36 months.</description>
        </group>
        <group group_id="E2">
          <title>Alemtuzumab 12 mg</title>
          <description>Alemtuzumab 12 mg/day was given by intravenous infusion on 5 consecutive days during the first month and on 3 consecutive days at months 12 and 24 (the latter at the treating physicians' discretion if the CD4+ T-cell count was &gt;=100*10^6 cells per liter).</description>
        </group>
        <group group_id="E3">
          <title>Alemtuzumab 24 mg</title>
          <description>Alemtuzumab 24 mg/day was given by intravenous infusion on 5 consecutive days during the first month and on 3 consecutive days at months 12 and 24 (the latter at the treating physicians' discretion if the CD4+ T-cell count was &gt;=100*10^6 cells per liter).</description>
        </group>
        <group group_id="E4">
          <title>Alemtuzumab (Pooled)</title>
          <description>Included all participants who received alemtuzumab 12 mg/day or 24 mg/day by intravenous infusion on 5 consecutive days during first month and on 3 consecutive days at months 12 and 24 (the latter at the treating physicians' discretion if the CD4+ T-cell count was &gt;=100*10^6 cells per liter).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="63" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Idiopathic thrombocytopenic purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Cardiovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune thyroiditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Basedow's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Thyroiditis subacute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Exophthalmos</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Enterocutaneous fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Erosive oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Gastroduodenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia oral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Paraesthesia oral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Salivary gland calculus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Catheter bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Cellulitis of male external genital organ</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Cervicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Herpes ophthalmic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Meningitis listeria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Meningitis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Limb traumatic amputation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Traumatic brain injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Traumatic lung injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Polyarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acoustic neuroma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Angiomyolipoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Glomus tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Cerebellar ataxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis relapse</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Myelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Paraparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Paresis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Sensory disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Sensory loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Abortion missed</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Abortion threatened</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Goodpasture's syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Micturition urgency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Ectropion of cervix</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Menometrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Ovarian cyst ruptured</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Ovarian disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="106" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="108" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="108" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="216" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Basedow's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="34" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="77" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="30" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="30" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="40" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="91" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Hyperthermia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="94" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="43" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="49" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="44" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Muscle tightness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="57" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Coordination abnormal</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="42" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="85" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="157" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="55" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis relapse</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="48" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Muscle spasticity</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="58" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Sensory disturbance</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="65" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Micturition urgency</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="35" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="30" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia facial</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="64" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="82" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="160" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="69" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>In multi-site studies, PI can publish after sponsor publishes or 18 months after study completion. PI gives sponsor a draft 60 days before publication. Sponsor can ask that confidential information be removed, and can defer publication another 60 days upon notifying PI that it will file a patent application on inventions contained in the draft.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Trial Transparency Team</name_or_title>
      <organization>Sanofi</organization>
      <email>Contact-us@sanofi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

